Mankind Pharma Limited has informed the Exchange regarding a press release dated July 31, 2025, titled "Please find attached Press Release".
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 2.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mankind Pharma reported Q1 FY26 revenue of INR 3,570 Cr, up 24.5% year-on-year, driven by 18.9% growth in domestic business and 81.1% surge in exports (boosted by BSV consolidation). EBITDA came in at INR 850 Cr with margins expanding modestly to 23.8% (up 20 bps YoY). However, profit after tax declined 17.4% YoY to INR 445 Cr, and diluted EPS fell 20.1% to INR 10.6, likely reflecting higher depreciation and finance costs from the BSV acquisition. The company maintained its #1 domestic rank with 4.9% market share and 1.8x volume outperformance versus the industry. Board approved an interim dividend of Rs 1 per share as Mankind marks 30 years of operations.
Strong top-line growth and market share gains are positive, but the sharp PAT decline despite EBITDA growth may raise investor concerns about acquisition-related costs. Interim dividend and volume outperformance provide some cushion for shareholders.